» Articles » PMID: 33680011

The Contribution of and Genetic Polymorphisms and Patients' Demographic Characteristics with Warfarin Maintenance Doses: A Suggested Warfarin Dosing Algorithm

Overview
Publisher Brieflands
Specialty Pharmacology
Date 2021 Mar 8
PMID 33680011
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The requirement of varying doses of warfarin for different individuals can be explained by environmental and genetic factors. We evaluated the frequency of vitamin K epoxide reductase complex subunit 1 () and cytochrome P450 2C9 () variants together with patientdemographic characteristics and investigated their association with warfarin dose requirement with the objective to suggest a warfarin dosing algorithm. In this study, 185 patients with heart valve replacement from West Azerbaijan, Iran were genotyped for (-1639 G>A) and (*2 and *3 alleles) by PCR-RFLP. Multiple linear regression was performed to create a new warfarin dosing algorithm. The frequency of variants in studied subjects was 12% for *2, 25.8% for  *3, and 60% for -1639A. The patients who carried the A allele at position -1639 and the variants *2 and *3 required a significantly lower daily mean warfarin dosage ( = 0.001). Statistical analysis also indicated a significant relationship between the daily maintenance dose of warfarin with age and blood pressure among the studied patients' cohort < 0.001). This study showed that in the heart valve replacement patients considering and polymorphisms beside demographic characteristics such as age will be helpful in pre-treatment dosing of warfarin which in turn reduces the complications associated with inappropriate warfarin dosing.

Citing Articles

Frameshift variation in the HMG-CoA reductase gene and unresponsiveness to cholesterol-lowering drugs in type 2 diabetes mellitus patients.

Khaleqsefat E, Rasul K, Kheder R, Baban S, Baban J Sci Rep. 2025; 15(1):288.

PMID: 39747109 PMC: 11695833. DOI: 10.1038/s41598-024-75461-7.


Construction of warfarin population pharmacokinetics and pharmacodynamics model in Han population based on Bayesian method.

Xia X, Cai X, Chen J, Jiang S, Zhang J Sci Rep. 2024; 14(1):14846.

PMID: 38937509 PMC: 11211351. DOI: 10.1038/s41598-024-65048-7.


Evaluation of a warfarin dosing algorithm including CYP2C9, VKORC1, and CYP4F2 polymorphisms and non-genetic determinants for the Iranian population.

Farajzadeh-Dehkordi M, Samiee-Rad F, Farzam S, Javadi A, Cheraghi S, Hamedi-Asl D Pharmacol Rep. 2023; 75(3):695-704.

PMID: 37039974 DOI: 10.1007/s43440-023-00476-2.

References
1.
Oner Ozgon G, Langaee T, Feng H, Buyru N, Ulutin T, Hatemi A . VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. Eur J Clin Pharmacol. 2008; 64(9):889-94. DOI: 10.1007/s00228-008-0507-5. View

2.
Fung E, Patsopoulos N, Belknap S, ORourke D, Robb J, Anderson J . Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Semin Thromb Hemost. 2012; 38(8):893-904. PMC: 4134937. DOI: 10.1055/s-0032-1328891. View

3.
Park S, Lee J, Chun S, Lee H, Kwon S, Kang D . VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients. J Stroke. 2013; 15(2):115-21. PMC: 3779671. DOI: 10.5853/jos.2013.15.2.115. View

4.
Bodin L, Horellou M, Flaujac C, Loriot M, Samama M . A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance. J Thromb Haemost. 2005; 3(7):1533-5. DOI: 10.1111/j.1538-7836.2005.01449.x. View

5.
Sconce E, Khan T, Wynne H, Avery P, Monkhouse L, King B . The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005; 106(7):2329-33. DOI: 10.1182/blood-2005-03-1108. View